US US20260242723A1
[0000] Hydrogels for organogenesis support organogenesis from mammalian cells, including human cells. The hydrogels contain a branched polyalkylene glycol functionalized with adhesion ligand peptides, such as integrin peptides and ECM peptides. In some forms, the hybrid hydrogels include a network of crosslinked branched synthetic polymers including a branched polyalkylene oxide polymer and a thiolated extracellular matrix polymer, preferably hyaluronic acid. In some forms, the synthetic hydrogels contain a branched polyalkylene glycol functionalized with GFOGER, RGD, YIGSR; and one or more ECM peptides, such as peptide(s) having affinity to fibronectin and/or peptide(s) having affinity to collagen and laminin. In some forms, the synthetic hydrogels possess desirable properties (e.g., a swelling ratio of ≤1.5 and/or a stiffness of ≤150 Pa) that allow the formation of perfusable vascular models in microfluidic devices. Also provided are methods of making the hydrogels and methods of using the hydrogels for organogenesis.
A document turning up in a search is not the same as a document that anticipates your claims. Our registered Patent Agents read the claims, not just the abstract, and tell you where you still have room.
Protect Your InventionBibliographic data via the European Patent Office's Open Patent Services (DOCDB) . Republished here for research and prior-art review. This page is not legal advice, and its presence in our index says nothing about the validity or enforceability of the document. For the Indian legal position (status, oppositions, renewals), see InPASS.